Statin use linked with a decrease in the conversion from high-grade prostatic intraepithelial neoplasia (HGPIN) to prostate cancer

Fowke, Jay H.; Motley, Saundra

doi:10.1093/carcin/bgy050

Cited by 9 publications

(6 citation statements)

References 45 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, statin usage has been linked to a reduced risk of prostate cancer death, improved recurrence-free survival after radical treatment [ 1 , 4 , 5 ], decreased risk of advanced prostate cancer, and decreased risk of conversion of high-grade intraepithelial neoplasia to prostate cancer [ 12 ]. Also, a recent study published by Longo et al found fluvastatin to induce PCa cell death in vitro [ 13 ]. There are few studies assessing statins’ effect on ADT-treated patients [ 14 , 15 ].…”

Section: Discussionmentioning

confidence: 99%

Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study

Peltomaa

Raittinen

Talala

et al. 2021

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Purpose Statins’ cholesterol-lowering efficacy is well-known. Recent epidemiological studies have found that inhibition of cholesterol synthesis may have beneficial effects on prostate cancer (PCa) patients, especially patients treated with androgen deprivation therapy (ADT). We evaluated statins’ effect on prostate cancer prognosis among patients treated with ADT. Materials and methods Our study population consisted of 8253 PCa patients detected among the study population of the Finnish randomized study of screening for prostate cancer. These were limited to 4428 men who initiated ADT during the follow-up. Cox proportional regression model adjusted for tumor clinical characteristics and comorbidities was used to estimate hazard ratios for risk of PSA relapse after ADT initiation and prostate cancer death. Results During the median follow-up of 6.3 years after the ADT initiation, there were 834 PCa deaths and 1565 PSA relapses in a study cohort. Statin use after ADT was associated with a decreased risk of PSA relapse (HR 0.73, 95% CI 0.65–0.82) and prostate cancer death (HR 0.82; 95% CI 0.69–0.96). In contrast, statin use defined with a one-year lag (HR 0.89, 95% CI 0.76–1.04), statin use before ADT initiation (HR 1.12, 95% CI 0.96–1.31), and use in the first year on ADT (HR 1.02, 95% CI 0.85–1.24) were not associated with prostate cancer death, without dose dependency. Conclusion Statin use after initiation of ADT, but not before, was associated with improved prostate cancer prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study

Peltomaa

Raittinen

Talala

et al. 2021

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…grade intraepithelial neoplasia to prostate cancer [12]. Also, a recent study published by Longo et al found fluvastatin to induce PCa cell death in vitro [13]. There are few studies assessing statins' effect on ADT-treated patients [14,15].…”

Section: Discussionmentioning

confidence: 99%

Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study

Peltomaa¹,

Talala²,

Taari³

et al. 2019

European Urology Supplements

View full text Add to dashboard Cite

Purpose Statins' cholesterol-lowering efficacy is well-known. Recent epidemiological studies have found that inhibition of cholesterol synthesis may have beneficial effects on prostate cancer (PCa) patients, especially patients treated with androgen deprivation therapy (ADT). We evaluated statins' effect on prostate cancer prognosis among patients treated with ADT. Materials and methods Our study population consisted of 8253 PCa patients detected among the study population of the Finnish randomized study of screening for prostate cancer. These were limited to 4428 men who initiated ADT during the follow-up. Cox proportional regression model adjusted for tumor clinical characteristics and comorbidities was used to estimate hazard ratios for risk of PSA relapse after ADT initiation and prostate cancer death. Results During the median follow-up of 6.3 years after the ADT initiation, there were 834 PCa deaths and 1565 PSA relapses in a study cohort. Statin use after ADT was associated with a decreased risk of PSA relapse (HR 0.73, 95% CI 0.65-0.82) and prostate cancer death (HR 0.82; 95% CI 0.69-0.96). In contrast, statin use defined with a one-year lag (HR 0.89, 95% CI 0.76-1.04), statin use before ADT initiation (HR 1.12, 95% CI 0.96-1.31), and use in the first year on ADT (HR 1.02, 95% CI 0.85-1.24) were not associated with prostate cancer death, without dose dependency. Conclusion Statin use after initiation of ADT, but not before, was associated with improved prostate cancer prognosis.

show abstract

“…Unlike other measures, BMI is readily available in the medical record and easily computed upon physical exam. BMI also predicts prostate cancer outcomes [ 4 , 5 , 28 – 30 ] and is associated with health outcomes in a trajectory similar to other measures of adiposity [ 31 , 32 ].…”

Section: Discussionmentioning

confidence: 99%

Performance of prostate cancer recurrence nomograms by obesity status: a retrospective analysis of a radical prostatectomy cohort

et al. 2018

View full text Add to dashboard Cite

BackgroundObesity has been associated with aggressive prostate cancer and poor outcomes. It is important to understand how prognostic tools for that guide prostate cancer treatment may be impacted by obesity. The goal of this study was to evaluate the predicting abilities of two prostate cancer (PCa) nomograms by obesity status.MethodsWe examined 1576 radical prostatectomy patients categorized into standard body mass index (BMI) groups. Patients were categorized into low, medium, and high risk groups for the Kattan and CaPSURE/CPDR scores, which are based on PSA value, Gleason score, tumor stage, and other patient data. Time to PCa recurrence was modeled as a function of obesity, risk group, and interactions.ResultsAs expected for the Kattan score, estimated hazard ratios (95% CI) indicated higher risk of recurrence for medium (HR = 2.99, 95% CI = 2.29, 3.88) and high (HR = 8.84, 95% CI = 5.91, 13.2) risk groups compared to low risk group. The associations were not statistically different across BMI groups. Results were consistent for the CaPSURE/CPDR score. However, the difference in risk of recurrence in the high risk versus low risk groups was larger for normal weight patients than the same estimate in the obese patients.ConclusionsWe observed no statistically significant difference in the association between PCa recurrence and prediction scores across BMI groups. However, our study indicates that there may be a stronger association between high risk status and PCa recurrence among normal weight patients compared to obese patients. This suggests that high risk status based on PCa nomogram scores may be most predictive among normal weight patients. Additional research in this area is needed.

show abstract

Statin use linked with a decrease in the conversion from high-grade prostatic intraepithelial neoplasia (HGPIN) to prostate cancer

Cited by 9 publications

References 45 publications

Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study

Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study

Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study

Performance of prostate cancer recurrence nomograms by obesity status: a retrospective analysis of a radical prostatectomy cohort

Contact Info

Product

Resources

About